Century Therapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Philadelphia, PA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $109 million and a loss of $10 million (its filed statements).
Product businessBiological Products, (No Diagnostic Substances)Philadelphia, PAfilings since 20218 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.6 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.4 out of ten, present 6.2 out of ten, future 6.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.1 out of ten. 2 warning events since 2021; the latest 2025-08-29. 31st percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 6.3 out of ten. +175.8% a year over 4 filed years; profitable in 0 of 4. 63rd percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 2.4 out of ten. CrossAssetData estimate 2.4/10, confidence 35 of 100 (one part). 24th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 6.9 out of ten. ROE -6%: lost 6¢ per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar. 69th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 8.0 out of ten. top 20% of 102 in its family; net margin -8.8%. 80th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 2.3 out of ten. bottom 22% of 108 in its family for leadership; chief executive since 2023. 22nd percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.1 out of ten. top 49% of 92 in its family for room to expand. 51st percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.4 out of ten. top 46% of 100 in its family for growth drivers. 54th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 9.0 out of ten. top 10% of 72 in its family for expectations against reality. 90th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-12 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-12 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-12 (on EDGAR). Newest filing: Form 8-K, 2026-10-02. Filings on record since 2021. Read from EDGAR 2026-10-12.
Who runs it
Pfeiffenberger, Brent (President and CEO); Russotti, Gregory (Title: Chief Technology and Manufacturing Officer); Cowan, Chad (Chief Scientific Officer); Carr, Douglas (SVP Finance & Operations); Truitt, Joseph (director); Blackwell, Kimberly (director); Lee, Han Myung (director); Murphy, Martin Patrick (director); Quimi, Daphne (director); Riva, Alessandro (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.